Tomorrow at 13 pm will come Respirator vd Johan Drott back to the BioStocks Studio for a company presentation. Follow the broadcast live on biostock.se!
See highlights from the interview below.
Check out the full interview below.
The content of BioStock's news and analysis is independent, but BioStock's operations are to some extent financed by companies in the industry. This post refers to a company from which BioStock has received funding.
BioStock studio: Respiratorius comments on status and future plans
Respiratorius develops drugs for common diseases such as cancer, severe asthma and COPD. CEO Johan Drott has visited BioStock's studio to answer our questions about the company's main pharmaceutical project, orphan drug status, Covid-19, how the EMA approved going directly to phase III after a successful phase I/IIa study with the lead candidate VAL001, the exit plans for the project and, of course, the ongoing SEK 25 million share issue. Hear the CEO tell us more!